Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review
✍ Scribed by Malcolm Steiger; W. Jost; F. Grandas; G. Van Camp
- Publisher
- Springer
- Year
- 2009
- Tongue
- English
- Weight
- 238 KB
- Volume
- 116
- Category
- Article
- ISSN
- 1435-1463
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objectives: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. ## Methods: Observational studies addressin
## Abstract Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists (DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non‐ergot DAs. We evaluated the effects of four DAs (pergolide, cabergoline, ropinir
## Abstract Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently